Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin®) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas

Şerefhanoğlu, Songül; Koca, Ebru; Goker, Hakan; Haznedaroğlu, İbrahim Celalettin; Çetiner, Deniz; Sayınalp, Nilgün; Büyükaşık, Yahya; Özcebe, Osman İlhami

Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin®) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas [Turk J Hematol]

Turk J Hematol. 2008; 25(4): 207-208

Failure of yttrium-90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (Zevalin®) with fatal side effects in relapsed/refractory diffuse large B-cell NHL transformed from other lymphomas

Songül Şerefhanoğlu, Ebru Koca, Hakan Goker, İbrahim Celalettin Haznedaroğlu, Deniz Çetiner, Nilgün Sayınalp, Yahya Büyükaşık, Osman İlhami Özcebe
Department Of Internal Medicine, Division Of Hematology, Hacettepe University School Of Medicine, Ankara, Turkey

Keywords: Ibritumomab Tiuxetan Radioimmunotherapy, NHL

Diğer lenfomalardan transforme olmuş relaps/refrakter difüz büyük B hücreli lenfomada ölümcül yan etkisi ile yttrium-90(90Y)-ibritumomab tiuxetan radyoimmunoterapi (Zevalin®)`nin başarısızlığı

Corresponding Author: Songül Şerefhanoğlu, Türkiye
Manuscript Language: English

CITE

Full Text PDF Download citation RIS EndNote BibTex Medlars Procite Reference Manager Send email to author Similar articles PubMed Google Scholar